41 results
8-K
EX-99.1
DSGN
Design Therapeutics, Inc.
7 Nov 24
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
4:06pm
) in anticipation of future IND submissions. Third Quarter 2024 Financial Results R&D Expenses: Research and development (R&D) expenses were $11.9 million … 30, (unaudited) Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Other income
8-K
EX-99.1
DSGN
Design Therapeutics, Inc.
5 Aug 24
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
8:01am
dystrophy type-1 (DM1) in anticipation of future IND submissions. Second Quarter 2024 Financial Results R&D Expenses: Research and development (R&D) expenses … ) Three Months Ended June 30, Six Months Ended June 30, (unaudited) Operating expenses: Research and development General and administrative Total operating
8-K
EX-99.1
yavnx3v
8 May 24
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
4:09pm
8-K
EX-99.1
05g4ws2utub22lxkegf
19 Mar 24
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
EX-99.1
zfxrefucf47uf0k8 gb
13 Nov 23
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
4:10pm
8-K
EX-99.1
405br9 d81x
14 Aug 23
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
4:07pm
8-K
EX-99.1
vi0k2fr2
9 May 23
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
4:13pm
8-K
EX-99.1
fb6a4wjgh23stlqu3h
3 Nov 22
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
4:09pm